New International Initiative Will Focus on Immunology Research and Treatments

Chiba University and UC San Diego launch $2 million collaborative partnership —

Immunology – and the idea that many diseases can best be addressed by boosting the body’s own immune response – is one of the hottest areas in medical research and clinical treatment. University of California San Diego School of Medicine and Chiba University School of Medicine in Japan have announced a new collaborative research center to investigate the most promising aspects of immunology, especially the area of mucosal immunology, and to speed development of clinical applications. … Read the Full Story from the UC San Diego Newsroom


Dr. Peter Ernst

Dr. Peter Ernst

Dr. Peter Ernst is co-directing the Chiba University-UC San Diego Immunology Initiative and associated research center.

Peter Ernst, DVM, PhD, is Professor of Medicine (Division of Gastroenterology), Professor of Pathology and Director of the Center for Veterinary Sciences and Comparative Medicine.

Blocking Tumor-Induced Inflammation Impacts Cancer Development

How tumors exploit microflora and immune cells to fuel growth

Researchers at the University of California, San Diego School of Medicine report the discovery of microbial–dependent mechanisms through which some cancers mount an inflammatory response that fuels their development and growth. … Read the full story from the UCSD Newsroom


Division of Gastroenterology physician-scientists Bernd Schnabl, MD, and Lars Eckmann, MD, along with former postdoctoral fellow Christoph H. Österreicher are coauthors of the study report.

Dr. Eckmann, professor of medicine, directs the UCSD Center for Tissue Repair, Epithelial Biology and Inflammation, and Transformation (C-TREAT), a National Institutes of Health Digestive Disease Research Development Center. In his research laboratory, he addresses the mechanisms governing infection-related intestinal disease and the host defenses against them; and the pathophysiology of intestinal inflammation.

Dr. Schnabl, assistant professor of medicine, leads a research laboratory whose primary purpose is to investigate cellular and molecular mechanisms involved in the progression of chronic liver diseases with a special emphasis on the gut-liver axis. In 2011, he was awarded a five-year R01 research grant from the National Institute on Alcohol Abuse and Alcoholism for his project, “Microbiome and Intestinal Innate Immune Response in Alcoholic Liver Disease.”

Read the published report in Nature [full text UCSD only]

Citation: Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl, B, Jauch D, Taniguchi K, Yu G-Y, Osterreicher CH, Hung KE, Datz C, Feng Y, Fearon ER, Oukka M, Tessarollo L, Coppola V, Yarovinsky F, Cheroutre H, Eckmann L, Trinchieri G, Karin M. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012/10/03, advance online publication. http://dx.doi.org/10.1038/nature11465.